Watch our webinar *Please ensure your pop-up blocker is turned off. KASTx Ventures is joined by Catalytic Life Sciences for an in-depth panel discussion on investing in and growing businesses in the biotech sector. In this webinar, you will learn from medical and financial experts from Canada and the United States as they discuss their own insights and learnings from their years of experience in this space. The current global climate has highlighted the need Read more…
What wasn’t possible just 20 years ago, is steadily increasing in both possibility and popularity: small biotechnology and biopharmaceutical companies facilitating their own commercialization process and launch. According to this article by McKinsey & Company, first-time launchers in biotech and biopharma have accounted for “more than a quarter of all new molecular entities submitted to the US FDA since 2016.” What does this mean? Small companies with a focus on differentiated sciences that don’t fit Read more…
Dataffinity Health has announced an official rebrand to celebrate its continued growth and expansion of its programs to 18 countries. The new name Lumiio reflects the guiding force the company has become to other stakeholders across the health communities they work with. KASTx Ventures has been an integral partner supporting Lumiio’s growth through expertise in corporate strategy, governance, business development, and contribution of several key team members through the KASTx Ventures fractional team model. Lumiio is an example of the success of the KASTx Ventures approach in partnering with Read more…
A new model is making waves that is changing the landscape for how life sciences companies can translate their technologies into use for the benefit of the public. The portfolio model presents a new way to diversify investment opportunities as well as the skills brought in to help work towards the success of biotech research.
KASTx Ventures is excited to announce the addition of Stuart Boswell as their new controller. After graduating from St. Francis Xavier University in 2015, Boswell launched his accounting career at big four company Ernst & Young which laid the foundation for his professional development.
KASTx Ventures is excited to announce a new collaboration with Dr. Geoff Frost, the first-ever Commercialization Fellow at the Hotchkiss Brain Institute, University of Calgary. Frost is a physiatrist who is working to develop an innovative technology that will help individuals experiencing chronic pain to track the effects of physiotherapy exercises.
KASTx is excited to announce Filip Korngut has joined their growing team as director, technology and information security. As a lifelong technology enthusiast, Korngut will play an instrumental role in helping both KASTx and their portfolio companies streamline and feel secure in their processes.
KASTx Ventures is excited to announce Mike Smith is the latest addition to their team of experts as Director, Capital Partnerships. Smith has had a love for finance for most of his life, taking an interest in stocks at a young age, eventually leading him to pursue a degree in commerce at the University of Toronto. But after an unexpected house visit at the age of 17, his early career took a different turn.
KASTx Ventures is excited to announce the addition of Jan Nighswander to our growing team of experts as our Director of Human Resources. The start to Nighswander’s career was something of a happy accident, she explained. Originally in production accounting in the energy industry, her passion was sparked when she had the opportunity to audit the employee benefits and pension plans of the company she was working for. She fell in love with the work, made the transition into the human resources department, and never looked back.
KASTx Ventures is pleased to announce the addition of Janet Petrillo to our team as Director of Clinical Development. Petrillo brings over 16 years of leading site clinical trials, and has established herself both nationally and internationally as an instrumental leader in the clinical research community. Her years of expertise in all levels of leadership will be incredibly valuable to our scientific partners in advising the development of trials from the ground-up.